Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2012 (2012), Article ID 654617, 3 pages
http://dx.doi.org/10.1155/2012/654617
Case Report

Metastatic Renal Cell Carcinoma Change Vascularity

Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, Japan

Received 21 July 2012; Accepted 8 August 2012

Academic Editors: T. Nomura and F. M. Solivetti

Copyright © 2012 Takeshi Azuma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor’s character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.